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Available online 13 January 2016Directed differentiation of iPS cells toward various tissue progenitors has been the focus of recent research.
Therefore, generation of tissue-speciﬁc reporter iPS cell lines provides better understanding of developmental
stages in iPS cells. This technical report describes an efﬁcient strategy for generation and validation of knock-in
reporter lines in human iPS cells using the Cas9-nickase system.
Here,we have generated a knock-in human iPS cell line for the earlymyogenic lineage speciﬁcation gene of PAX7.
By introduction of site-speciﬁc double-stranded breaks (DSB) in the genomic locus of PAX7 using CRISPR/Cas9
nickase pairs, a 2A-GFP reporter with selection markers has been incorporated before the stop codon of the
PAX7 gene at the last exon. After positive and negative selection, single cell-derived human iPS clones have
been isolated and sequenced for in-frame positioning of the reporter construct.
Finally, by using a nuclease-dead Cas9 activator (dCas9-VP160) system, the promoter region of PAX7 has been
targeted for transient gene induction to validate the GFP reporter activity. This was conﬁrmed by ﬂow cytometry
analysis and immunostaining for PAX7 and GFP. This technical report provides a practical guideline for genera-
tion and validation of knock-in reporters using CRISPR/Cas9 system.
Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Human iPS cells provide an unprecedented opportunity for the sci-
ence community to model and study different disorders in vitro (Inoue
et al., 2014). These cells can be used for many in vitro applications
such as disease modeling, drug screening, genome editing and even in
vivo regenerative purposes (Tedesco et al., 2012; Wang et al., 2012;
Xie et al., 2014; Zou et al., 2011; Soldner et al., 2009; Dimos et al.,
2008; Ebert et al., 2009; Moretti et al., 2010; Raya et al., 2009; Maehr
et al., 2009). Therefore, generation of different lineage progenitors and
tissues from iPS cells has been considered the cornerstone of iPS tech-
nology (Mauritz et al., 2008; Zhang et al., 2009; Choi et al., 2009;
Grigoriadis et al., 2010). Thus, generation of lineage-speciﬁc reporter
ES/iPS cell lines enables prospective identiﬁcation and isolation ofgenerative Medicine (CSCRM),
for the Prevention of Human
ter at Houston, 1825 Pressler
i).
ss article under the CC BY-NC-ND licvarious progenitors from differentiating cells and allows optimization
of differentiation protocols.
Knock-in reporter cells have been generated through site-speciﬁc
gene targeting and homologous recombination (HR) mediated inclu-
sion of the reporter cassette in the appropriate genomic locus (Leavitt
& Hamlett, 2011; Zwaka & Thomson, 2003). This allowed for in-frame
inclusion of the reporter cassette without any undesirable side effects
associated with random integration based methods.
However, the low efﬁciency of HR in human iPS cells makes it hard
for gene modiﬁcation in human iPS cells (Zwaka & Thomson, 2003;
Xue et al., 2009; Davis et al., 2008; Ruby & Zheng, 2009). Nevertheless,
nuclease-mediated introductions of site-speciﬁc DNA double-stranded
breaks (DSBs) have signiﬁcantly increased the efﬁciency of HR. These
include site-speciﬁc nucleases such as zinc-ﬁnger (ZFN) and transcrip-
tion activator-like effector nucleases (TALENs), which allowed for pre-
cise gene editing (Wang et al., 2012; Zou et al., 2011; Kim et al., 1996;
Urnov et al., 2010; Carroll et al., 2006; Deng et al., 2012; Ma et al.,
2013; Maetzel et al., 2014; Shin et al., 2014). The only limiting factor
with these methods is their complex time-consuming design.
Fortunately, a new class of RNA-guided nucleases has been devel-
oped frommicrobial adaptive immune systems (i.e. clustered regularlyense (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Cas9-CRISPR/Cas9-systems) (Cong et al., 2013; Mali et al., 2013a). This
system provides a very simple and efﬁcient design for site-speciﬁc
targeting of genomic DNA. A newer version of Cas9 uses a D10Amutant
of Cas9 (Cas9n) to introduce a single-strand nick in DNA (Mali et al.,
2013b; Ran et al., 2013a). By using as a pair to target a speciﬁc locus,
Cas9n pair increases site-speciﬁcity while reduces the off-target muta-
tions (Shen et al., 2014). Therefore, in this technical report, we used
CRISPR/Cas9n system for generation of the human iPS cell reporters.
In this case, we decided to generate a PAX7 skeletal muscle reporter
iPS cell line.
Pax7 and PAX3 play key roles in speciﬁcation of neural crest devel-
opment as well as skeletal muscle speciﬁcation during embryogenesis
(Buckingham & Relaix, 2007; Jostes et al., 1990; Basch et al., 2006). For
skeletal myogenesis, PAX3/7 positive cells specify early paraxial meso-
dermal cells which enter the myogenic program and govern skeletal
myogenesis during embryonic and fetal development (Buckingham &
Relaix, 2007; Jostes et al., 1990; Lagha et al., 2008; Relaix et al., 2006;
Relaix et al., 2004; Relaix et al., 2005). These cells differentiate intomyo-
blasts and move to different parts of body/limb to form mature
myoﬁbers or stay quiescent to form muscle adult stem cells/satellite
cells. Due to the important role of PAX7 in this process especially for sat-
ellite cell formation (Seale et al., 2000),we decided to choose themuscle
speciﬁc transcriptional isoforms (1 and 2) of PAX7 for generation of the
reporter human iPS cell line (Barr et al., 1999; Vorobyov & Horst, 2004).
In this technical report, we designed a Cas9n based strategy to gen-
erate the reporter. In addition, by using a nuclease-dead Cas9 (dCas9)
gene activation/CRISPR-on system (dCas9-VP160 activator) (Cheng
et al., 2013),we induced PAX7 transcription to validate theGFP reporter
function.
2. Materials and methods
2.1. sgRNA design and Cas9 nickase (Cas9n) vector assembly
Cas9 target sites were identiﬁed using an online CRISPR design tool
(crispr.mit.edu) (Ran et al., 2013b). Brieﬂy, 200 bp DNA sequences of
human PAX7 gene ﬂanking the stop codon (100 bp before and after
the stop codon) were used for designing the sgRNAs. Then, four pairs
of sgRNAwere selected to generate the optimal 5′-overhang arm length
for efﬁcient cutting (Ran et al., 2013a). For each target site, a speciﬁc
Cas9n vector was made. Brieﬂy, a Cas9 nickase vector (hSpCas9n
nickase — pX335, # 42335 from addgene) (Cong et al., 2013) was
digested using BbsI and a pair of annealed oligos (20 bp target
sequences) was cloned into the guide RNA locus (Ran et al., 2013b).
The vectors were then sequenced for conﬁrmation.
2.2. SURVEYOR assay for Cas9n pairs
Assembled Cas9n pairs were tested by transfecting 293T cells. Brief-
ly, 0.5 μg of each plasmid was used for transfection of 293T cells. Three
days after transfection, DNA from targeted and non-targeted cells was
harvested and ampliﬁed by PCR for the targeted region. Then, PCR prod-
ucts were hybridized using a thermocycler to allow heteroduplex
formation from targeted and non-targeted DNA. Later on, 400 ng of
hybridized DNA was treated with a SURVEYOR nuclease and DNA frag-
ments were analyzed by agarose gel electrophoresis to identify the
presence of expected bands. The best pair (5 + 7) with the highest
cutting efﬁciency was chosen for targeting.
2.3. Generation of targeting vector
A BAC clone for the human PAX7 was obtained from CHORI (BAC
RP11-164D21). To generate the targeting vector, we used a highly
efﬁcient recombination-based cloning method in bacteria (Wu et al.,
2008). Brieﬂy, homology arms (5′ — 1.2 kb; 3′ — 4.4 kb) along withtarget region were captured into a gateway compatible vector (pStart-
K, # 20346 from addgene) (Wu et al., 2008) using recombineering.
After introduction of a cutting site with a selection sequence (AscI-
Cat-AscI) using another recombineering reaction, the reporter with an
excisable selection sequence (2A-GFP-loxP-EF1a-RFP-2A-Puro-loxP
fragment from HR130PA-1 vector, System Biosciences — SBI) was
cloned into the AscI cutting sites using a blunt-end ligation. Finally,
through a gateway recombination, the modiﬁed genomic fragment
was switched into another vector which contained the negative selec-
tion (tk) as well as unique linearization sites. The ﬁnal vector was line-
arized before using for targeting.
2.4. Validation of targeting efﬁciency in 293T cells
In order to validate the efﬁciency of the targeting construct and
Cas9n vectors, 1 × 107 of 293T cells were electroporated (Gene Pulser
Xcell — Bio-Rad, 250 V, 250 μF, ∞ Ώ) with the targeting cocktail (10 μg
of Cas9n plus 50 μg of linearized targeting vector) and after positive
and negative selection (0.75 μg/ml puromycin and 200 nM FIAU from
day 3 to day 11), the expanded 293T cell clumps were analyzed for
RFP using a ﬂuorescent microscope. Positive individual clones were
harvested and PCR-screened for targeting efﬁciency (PCR primers
were designed to span the outside 5′ homology arm and 2A-GFP region
to ensure the right target locus).
2.5. Generation of reporter human iPS clones
After validation of Cas9n pairs using SURVEYOR assay and targeting
vector in 293T cells, fully characterized integration-free human iPS cells
(DF19-9, WiCell) (Yu et al., 2009) have been used for generation of
human reporter clones. The human iPS cells were expanded onMatrigel
in feeder conditioned medium for a few days and after harvesting,
1 × 107 cells were electroporated (Gene Pulser Xcell — Bio-Rad, 250 V,
250 μF,∞Ώ) using 10 μg of Cas9 vectors plus 50 μg of linearized targeting
vector for PAX7. After electroporation, cells were expanded for a few
days and selection was done by addition of positive and negative selec-
tion (0.75 μg/ml puromycin and 200 nM FIAU) for 2 weeks. After selec-
tion, RFP+ clones were picked up for expansion and screened by PCR.
2.6. PCR and sequencing validation of reporter clones
PCR primers were designed to span outside the 5′ homology arm up
to 2A-GFP region as well as covering the nicking sites of Cas9 nickase
pair. PCR products were sequenced to ensure in-frame positioning of
the reporter/selection fragment and to rule out the presence of indels
at cutting sites of Cas9n pairs. Furthermore, to identify homozygous
clones for reporters, PCR primers were designed to identify intact
PAX7 as well as the targeted allele.
2.7. Southern blot validation of transgene copy number
In order to prove the correct integration site of the transgene and ex-
clude any random integration of the transgene, a southern blot strategy
was designed using an internal probewithin the GFP. The genomic DNA
from the reporter hiPS cells was extracted and 5 μg of genomic DNA
from each cell linewas digestedwith EcoRV, separated in a 0.9% agarose
gel and transferred to aHybondN+membrane as described before (Xue
et al., 2016). The genomic DNA on the membrane was then hybridized
with a Digoxigenin (DIG)-labeled internal probe derived from partial
GFP sequence.
2.8. sgRNA design for dCas9-VP160 activator and vector assembly
In order to evaluate reporter activity in targeted iPS clones, we used
a nuclease-dead Cas9 activator system (pAC93-pmax-dCas9VP160,
# 48225 from addgene) (Cheng et al., 2013). sgRNAs were designed to
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ters available at the UCSC genome browser database. Multiple target
sites were identiﬁed and annealed oligos were cloned into the activator
vector. Generated vectors were sequenced for conﬁrmation.2.9. Reporter validation using dCa9-VP160 transient activation
dCas9-VP160 activator constructs were tested on human iPS cells to
validate their efﬁciency for gene activation. Individual or pooled con-
structs (0.5 μg) were transfected into human iPS cells using Lipofecta-
mine LTX transfection reagent (Life technologies) and three days after
transfection the cells were harvested for RNA extraction. cDNA was
made using reverse-transcription and RT-PCR was performed using
TaqMan assays for PAX7 to identify the best activators. After choosing
the best activators, the PAX7–GFP knock-in human iPS cells were
transfected again and were harvested for GFP analysis using a
FACSAria system and were gated against non-induced cells. For immu-
nostaining, GFP negative and positive cells were sorted and ﬁxed
using 4% PFA/PBS and after blocking, were stained for PAX7 (1:100,
Monoclonal mouse IgG1 Clone # Pax7, R&D Systems) and DAPI. GFPFig. 1. PAX7 gene targeting strategy and sgRNA design and evaluation. a) The PAX7 gene is tar
contains an excisable loxP fragment of selection markers is incorporated using a Cas9 nickas
analyzed for potential sgRNA target regions. Four sgRNAs along with their cutting/nicking
cutting efﬁciency of each pair in 293T cells using a SURVEYOR assay. Red arrows indicate apprwas directly detected (not stained) on ﬁxed cells. Co-expression of nu-
clear PAX7 and cytoplasmic GFP validated the proper reporter activity.
2.10. Western blot for PAX7
After dCas9 activator transfection, cells were collected and lysed
with 1× SDS loading buffer. The sample was loaded on a SDS-polyacryl-
amide gel electrophoresis (SDS-PAGE) gel and then electro-transferred
onto a PVDFmembrane. Themembranewas subsequently blockedwith
3% BSA and incubated with mouse monoclonal anti-Pax7 antibody
(1:1000, Monoclonal mouse IgG1 Clone # Pax7, R&D Systems) and
then HRP-conjugated goat anti-mouse IgG antibodies (1:4000, SC-
2005, Santa Cruz).
3. Results
3.1. Cas9n pairs can target PAX7 locus in 293T cells
To generate Cas9 mediated knock in reporter lines for PAX7 in
human iPS cells, we ﬁrst analyzed the 100 bp regions ﬂanking the last
exon stop codon for the PAX7 gene.geted at the last exon (exon 8) before the stop codon and a 2A-GFP reporter cassette that
e mediated homology recombination. b) Flanking regions of the PAX7 stop codon were
sites are marked as well as their associated NGG PAM sequences. c) Gel demonstrates
oximate expected bands. Pair 5 + 7 was chosen for subsequent experiments.
Fig. 2. Targeting vector design and construction. As demonstrated above, (a) the genomic fragment containing the targeting exon and homology arms was captured in a gateway vector
using recombineering in bacteria. Subsequently rareAscI cutting siteswere introduced before the stop codon for (b) cut and paste in-frame cloning of 2A-GFP alongwith selectionmarkers.
(c) Finally the vector was switched to another gateway vector containing negative selection and linearization site.
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for PAX7 and annealed oligos were cloned into Cas9n vectors. Each
pair was transfected into 293T cells and a SURVEYOR assay was per-
formed to determine the cutting efﬁciency of each pair. These data are
shown in Fig. 1c. As demonstrated, tested pairs generated expected cut-
ting bands after digestion with the SURVEYOR nuclease indicating their
cutting ability for the targeted region. Pair 5 + 7 was chosen for subse-
quent experiments.Fig. 3.Generation of knock-in human iPS cell lines for PAX7. a) The image demonstrates a targe
demonstrate the PCR strategy to identify homozygous clones for the targeting vector. The upper
shows wild type band. As shown, 4 clones (marked with green numbers on top) out of 14 pos3.2. Targeting vector assembly using recombineering
Next, we made the targeting vector for PAX7. Human PAX7 expres-
sion is controlled by differential transcriptional termination in the last
exons, exon 8 or exon 9 which produces different transcriptional
isoforms. As we (Darabi et al., 2012) and others (Barr et al., 1999;
Vorobyov & Horst, 2004) have shown that the ﬁrst transcriptionalted human iPS clone 2weeks post-selection with uniform expression of RFP. b) Gel images
gel indicates that 14 out of 19 clones have at least one copy of targeted allele. The lower gel
itive clones lacked the wild type band indicating that both alleles are targeted.
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targeting vector was designed to target exon 8 termination isoforms.
As described in Fig. 2, the targeting locus along with both homology
arms were captured using recombineering and the 2A-GFP reporter
along with the selection cassette was inserted using a blunt-end liga-
tion. Later on, the backbone vector was switched into a gateway vector
which contained the negative selection (tk) along with unique lineari-
zation sites. The ﬁnal vector was validated by sequencing to ensure in-
frame positioning of the reporter/selection cassette.
3.3. Cas9n mediated homologous recombination is efﬁcient in 293T cells
In order to validate the targeting strategy of the system, we decided
to target 293T cells with the HR vector and Cas9n pairs to validate them
before targeting the human iPS cells. Therefore, 293T cellswere targeted
using PAX7 HR/Cas9n vector cocktails using electroporation. Two days
after electroporation, positive and negative selection was started using
puromycin and FIAU for 2 weeks. During this timeframe, resistant
clones were beginning to emerge in the culture. Using a ﬂuorescentmi-
croscope we were able to identify RFP positive clones of 293T cells.
These data are presented in Supplementary Fig. 1a. As shown, positiveFig. 4. Sequencing and southern blot validation of PAX7 reporter clones. a) Boxes 1, 2 and 3
indicating in-frame positioning of the PAX7 reporter cassette. Box 1 covers the junction of 5′
exon 8 with the reporter cassette and box 3 covers the 3′ end at nicking site B. No indels we
blot strategy – to identify the right integration site and exclude the presence of any ran
demonstrated in the upper image. The expected 6.4 kb band following EcoRV digestion of t
hybridization results indicating that 3 out of 4 screened clones showed single correct integra
the experiments.clones were picked up and screened with a PCR reaction designed to
span outside the 5′ homology arm up to 2A-GFP region (1.6 kb area as
shown in Supplementary Fig. 1b). We were able to identify correct in-
frame targeted 293T cell clones as shown by conﬁrmatory PCR.
3.4. Human iPS cells can be targeted efﬁciently using Cas9n mediated HR
After validation of the targeting efﬁciency in 293T cells, human iPS
cells were used to generate reporter lines for PAX7. For this reason, a
well characterized, normal karyotype, integration-free human iPS cell
line (DF19-9, WiCell) was chosen to be used (Yu et al., 2009).
Human iPS cells were expanded in feeder-free Matrigel coated
plates in conditioned medium and after the harvest, electroporated
with targeting vector cocktails containing Csa9n pairs and a HR vector
for PAX7.
The cells were plated after electroporation and positive and negative
drug selection were started three days later for the duration of two
weeks. During this time, individual resistant targeted iPS clones started
to grow and expressed RFP as demonstrated in Fig. 3a. RFP-positive
clones were then individually picked up and were screened for further
conﬁrmation.show sequencing results of the PCR products in one of the positive homozygous clones
homology arm with the genomic DNA (nicking site A). Box 2 covers the junction of the
re detected in the represented clone. b) Reporter clones were analyzed using a southern
dom integration – using an internal probe for GFP region of the reporter cassette as
he genomic DNA is marked on the image. The image on the right demonstrates probe
tion. Only one clone (clone 10) showed two integration sites which was excluded from
225J. Wu et al. / Stem Cell Research 16 (2016) 220–2283.5. Reporter clones show in-frame positioning and normal pluripotency
markers
In order to conﬁrm in-frame positioning of the reporter cassette and
exclude any possible indels at the Cas9 mediated cutting sites, RFP pos-
itive clones were screened using a PCR spanning outside of 5′ homology
arm up to the 2A-GFP reporter site. The primer binding sites are shown
in Fig. 3b (upper panel). As the gel image indicates,most of the screened
clones showed the correct knock-in placement of the reporter cassette
(14 out of 19 clones screened — 73% efﬁciency in targeting at least one
allele)which conﬁrmed high efﬁciency of the targeting using Cas9nme-
diated HR.
Also in order to identify homozygous clones for transgene, PCR
primers were designed to identify the intact genomic PAX7 gene. This
data is presented in Fig. 3b (lower panel).
We were able to identify 4 clones (21% of total screened clones)
which lacked the wild type PAX7 band indicating that both alleles
were targeted by the reporter construct. This is important for reporter
activity evaluation since 2A-GFP allows for bicistronic expression of
the target gene along with GFP. Therefore, homozygous clones demon-
strate brighter GFP reporter activity.
Moreover, to conﬁrm in-frame positioning of the reporter cassette
and the absence of any indels, PCRproductswere sequenced at three re-
gions (genomic DNA to 5′ homology arm junction at nicking site A, exon
8 to 2A-GFP junction and at 3′ nicking site B, asmarked at boxes 1, 2 and
3 in Fig. 4a). As shown, we were able to identify the right clones with
correct in-frame positioning of the reporter cassette without any indels.Fig. 5. dCas9-VP160mediated activation of PAX7 gene and FACS analysis of the reporter clones.
which includes a 239 bp sequence identiﬁed by DNase I hypersensitivity cluster data in UCS
Supplementary Fig. 3. b) Real time PCR for PAX7 shows proper induction of PAX7 three days p
group showed higher induction. Data are mean of 2 independent sets and are normalized to th
cell clone indicates proper GFP reporter activity 3 days post transfection.Furthermore, to prove the right integration site of transgene and ex-
clude any random integration, a southern blot was performed using an
internal probewithin the GFP region. Fig. 4b demonstrates the southern
blot strategy and the expected 6.4 kb band in case of correct integration.
As shown in the gel image, among the 4 screened clones, 3 showed the
correct 6.4 kb single integration bands. Only one clone (#10) showed
one extra (random integration) band which was excluded from the
study.
Finally, selected reporter iPS clones were evaluated for normal kar-
yotype and pluripotency markers including Oct3/4, Sox2, Nanog, Lin28
and SSEA-4 to conﬁrm their pluripotency after the targeting/selection
experiments. These data are demonstrated in Supplementary Fig. 2
which indicate that the reporter clones keep their pluripotencymarkers.
Also, two homozygous reporter clones were screened for chromosomal
abnormalities which both retained their parental cell line karyotype
without any new abnormality after targeting.
3.6. Reporter activity validation using dCas9 activators
After characterization of PAX7 reporter human iPS cell clones, the
cells were tested for reporter activity. To do this, a dead Cas9 (dCas9-
VP160) activator approach was implemented to activate the endoge-
nous PAX7 (Cheng et al., 2013).
As Fig. 5a demonstrates, the upstream open chromatin region to
transcription start site (TSS) for PAX7 (based on DNase I hypersensitiv-
ity cluster data in UCSC genome browser— Supplementary Fig. 3a) was
analyzed for potential gRNA target sites. Target sites were determineda) The diagram shows an open chromatin region in human iPS cells used for sgRNA design
C genome browser database. The sequence of each sgRNA and their oligos are listed in
ost-transfection of human iPS cells with each activator or as pooled. As indicated, pooled
e fold of GAPDH. c) FACS proﬁle of non-induced vs. dCas9 activator induced reporter iPS
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activator vector. For PAX7, six individual sgRNA activator vectors were
designed and constructed. The sgRNA sequences and their oligos are
demonstrated in Supplementary Fig. 3b. Then each activator (individu-
ally or as pooled) was transfected into reporter iPS clones and RNAwas
harvested for RT-PCR gene expression using TaqMan assay for PAX7
expression.
As data in Fig. 5b indicates, dCas9 activation resulted in an increased
PAX7 expression which was higher in the case of pooled transfection.
At the next step, the cells were transfected again for PAX7 activation
in reporter iPS clones using the pooled dCas9 activators. As demonstrat-
ed in Fig. 5c, three days after the transfection, FACS analysis proved the
proper activation of the reporter cassette by expression of the GFP in
dCas9 activator transfected reporter cells compared to non-transfected
control.
At last, co-expression of GFP and PAX7 was conﬁrmed by direct mi-
croscopy and immunoﬂuorescent staining of the cells. Therefore, after
dCas9 activation for PAX7, non-induced and dCas9 induced cells were
examined by direct ﬂuorescent microscopy for GFP validation. This
data is presented in Fig. 6a which clearly demonstrates proper cytoplas-
mic expression of GFP 3 days after dCas9 activator transfection.
Furthermore, in order to prove the PAX7 expression and to rule out
expression of any fused protein between PAX7 and GFP, a western blot
was done on activated cells. The membrane image at Fig. 6b conﬁrmedFig. 6. Live cell ﬂuorescent microscopy, western blot and immunostaining of the sorted cells fo
imaging of the reporter lines before and after dCas9 activator transfection demonstrates clear cy
PAX7 (57 kDa) and lack of any visible fusedprotein band (fused PAX7–GFP, 87 kDa) following dC
After dCas9 activation, GFP negative and positive cells were sorted and plated for immunoﬂuor
induced iPS cells demonstrate proper co-expression of nuclear PAX7 along with GFP reporter,proper expression of PAX7 (57 kDa) without visible expression of fused
protein (87 kDa). Finally, negative and positive cells were sorted and
plated for immunoﬂuorescent (IF) staining. After the sort, cells were
ﬁxed, stained for PAX7 and evaluated for co-expression of cytoplasmic
GFP signal and nuclear expression of PAX7. As data on Fig. 6c indicates,
while negative cells do not express any PAX7 or GFP, dCas9 activator
transfected reporter cells co-express PAX7 along with GFP (Fig. 6c)
which conﬁrmed the proper activity of the reporter cassette following
activation of endogenous PAX7 gene expression.
4. Discussion
Generation of knock-in reporter cell lines is a classical method to
evaluate developmental gene activations during cell differentiation.
The study of different pathway modiﬁers and signaling molecules
along with chemical library screening for different potential activators
or inhibitors are among other important applications of reporter cell
lines. Obviously, in the case of embryonic stem cells (ES) or iPS cells,
generation of reporter lines for lineage-speciﬁc genes, enables re-
searchers to study temporal development of different lineage progeni-
tors during in vitro differentiation. Since ES/iPS cells recapitulate early
developmental stages of the embryo, reporter lines can provide invalu-
able information regarding the pattern and the effect of different signal-
ing pathways during early developmental stages. Therefore manyr PAX7 and GFP conﬁrm the reporter activity in dCas9 induced cells. a) Direct ﬂuorescent
toplasmic GFP expression in induced cells. b)Western blot for PAX7 conﬁrms expression of
as9 activation. c) Immunostaining on theGFP negative andpositive fractions after the sort.
escent staining. While GFP negative cells do not express any PAX7 or GFP, dCas9 activator
which validates the functionality of the reporter iPS cells.
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cell lines from ES/iPS cells.
Though initial efforts have conﬁrmed feasibility of HR targeting in
ES/iPS cells, the overall efﬁciency was low (Leavitt & Hamlett, 2011;
Xue et al., 2009; Davis et al., 2008; Ruby & Zheng, 2009). Fortunately
with the availability of site-speciﬁc endonuclease systems such as
ZFNs, TALENS and more recently CRISPR/Cas9 system, induction of a
double-stranded break (DSB) at a speciﬁc site of the genome signiﬁcant-
ly improves HR targeting in ES/iPS cells (Bottcher et al., 2014; Rong
et al., 2014; Xue et al., 2014; Yu et al., 2014). Speciﬁcally in the case of
Cas9 nickase system, its easier design/construction and the reduced
risk of off-target side-effectsmake it a very favorable choice for improv-
ing HR targeting of the ES/iPS cells.
In this technical report, we have generated a knock-in reporter iPS
cell line for early myogenic gene of PAX7. As myogenic differentiation
of ES/iPS cells generally shows lower efﬁciency compared to other me-
sodermal progenitors such as cardiac or hematopoietic lineages, these
reporter lines can serve as an invaluable tool to study the differential
pattern and speciﬁcation of myogenic progenitors during in vitro differ-
entiation of human ES/iPS cells.
As our data demonstrates, we have designed a bicistronic reporter
expression system by the incorporation of a 2A-GFP reporter cassette
before the stop codon for PAX7 which allows a strong and precise
expression of the GFP reporter upon gene activation. Also we have
achieved a high success rate in the generation of knock-in human iPS
cells for PAX7 (more than 70% of the selected iPS clones demonstrated
proper in-frame positioning of the reporter cassette at least in one
allele). Moreover, among screened clones we were able to identify
homozygous clones with both alleles targeted at a rate of 20% which is
another remarkable ﬁnding of this strategy.
Another important advantage of this technical report is the success-
ful application of dCas9 activators for validation of PAX7 knock-in
reporter cells (Cheng et al., 2013). By design and assembly of site-
speciﬁc dCas9 activators for PAX7 in human iPS cells, these activators
have been screened for induction efﬁciency. As our data indicated,
reporter lines have been successfully validated for reporter activity of
PAX7 using this approach. Therefore, we not only veriﬁed proper re-
porter activity of the selected clones, we have also demonstrated the ef-
ﬁciency of dCas9 activators for PAX7 gene induction in human iPS cells.
This approach may be also used for directed differentiation of human
iPS cells toward early PAX7 positive myogenic progenitors.
5. Conclusions
Taken together, this study reports the ﬁrst successful generation of
CRISPR/Cas9n mediated knock-in reporter human iPS cell lines for
PAX7 with precise targeting and high efﬁciency. Moreover, it has vali-
dated the application of dCas9 activator system for PAX7 gene induction
in human iPS cells. Therefore, generated PAX7 reporter human iPS lines
can be used for the study of early skeletal myogenic differentiation,
chemical screening and identiﬁcation of early myogenic progenitors.
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